These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
JAK1 Manuscript end.pdf (1.31 MB)
The Potential of JAK/STAT Pathway Inhibition as a New Treatment Strategy to Control Cytokine Release Syndrome in COVID-19
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 14.09.2020 and posted on 15.09.2020by Mohammad Seyedhamzeh, Hazha Omar Othman, Ali aghajani Sharivar, Fatemeh Aliabadi, Mehdi Shafiee Ardestani, Hamidreza Pazoki-Toroudi
COVID-19, a pandemic affecting virus, which is caused by the current SARS-CoV2 coronavirus.
The present research is performed on anti virus and immune-modulating therapies. Cytokine
storms are the toxic drivers and mortality caused by various human viral infections. In addition,
the intensity was linked to an elevated risk of acute respiratory failure, myocardial injury, and
mortality in SARS-CoV-2-infected patients. The Janus kinase (JAK) therapeutic inhibitor class
showed significant clinical benefits in anti-inflammatory and anti-viral effects. Among them,
filgotinib has been approved as an active JAK inhibitor by decreasing biomarkers with main
immune reaction functions and markers supporting matrix-degradation, angiogenesis, leukocyte
adhesion, and recruitment in both research trials. In this study, we tried to get an insight into the
choice of this drug in controlling the jack, to treat Covid 19 using drug design methods will be